SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 174051.
  • 2
    Symmons DP. Lymphoma and rheumatoid arthritis—again [editorial]. Rheumatology (Oxford) 2007; 46: 12.
  • 3
    Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 141420.
  • 4
    Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699703.
  • 5
    Franklin JP, Symmons DP, Silman AJ. Risk of lymphoma in patients with RA treated with anti-TNFα agents. Ann Rheum Dis 2005; 64: 6578.
  • 6
    Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006; 65: 61722.
  • 7
    Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692701.
  • 8
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 227585.
  • 9
    Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al [editorial]. Arthritis Res Ther 2006; 8: 111.
  • 10
    Matteson EL, Bongartz T, Sutton AJ, Buchan I. Response to commentary by Dixon and Silman on the systematic review and meta-analysis by Bongartz et al [letter]. Arthritis Res Ther 2006; 8: 404.
  • 11
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 12
    Doody MM, Hayes HM, Bilgrad R. Comparability of National Death Index Plus and standard procedures for determining causes of death in epidemiologic studies. Ann Epidemiol 2001; 11: 4650.
  • 13
    National Cancer Institute. Surveillance, epidemiology and end results. URL: http://seer.cancer.gov/.
  • 14
    Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies and clinical trials: the Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005; 32: 24105.
  • 15
    Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005; 52: 38739.